EyePoint Pharmaceuticals (EYPT) Liabilities and Shareholders Equity: 2011-2018
Historic Liabilities and Shareholders Equity for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Jun 2018 value amounting to $71.7 million.
- EyePoint Pharmaceuticals' Liabilities and Shareholders Equity rose 63.19% to $81.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $320.5 million, marking a year-over-year increase of 232.66%. This contributed to the annual value of $71.7 million for FY2018, which is 283.73% up from last year.
- Latest data reveals that EyePoint Pharmaceuticals reported Liabilities and Shareholders Equity of $71.7 million as of FY2018, which was up 283.73% from $18.7 million recorded in FY2017.
- EyePoint Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $71.7 million during FY2018, with a 5-year trough of $18.7 million in FY2017.
- For the 3-year period, EyePoint Pharmaceuticals' Liabilities and Shareholders Equity averaged around $40.7 million, with its median value being $31.6 million (2016).
- Per our database at Business Quant, EyePoint Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 40.93% in 2017 and then soared by 283.73% in 2018.
- Yearly analysis of 5 years shows EyePoint Pharmaceuticals' Liabilities and Shareholders Equity stood at $22.7 million in 2014, then soared by 42.77% to $32.4 million in 2015, then declined by 2.31% to $31.6 million in 2016, then slumped by 40.93% to $18.7 million in 2017, then skyrocketed by 283.73% to $71.7 million in 2018.